. 2022 Jan 30;44(1):34–42. doi: 10.1080/0886022X.2021.2011746

Table 4.

Distribution of acquired thrombophilic risk factors in the study subjects.

Parameters	Cut off	Group 1 (n%)	Group 2 (n%)	Total (n%)	p Value
Lipoprotein (a) (mg/dl)	>20 (mg/dl)	21 (42%)	48 (96%)	69 (61%)	<0.001^a
Lipoprotein (a) (mg/dl)	< 20 (mg/dl)	29 (58 %)	2 (4%)	31 (31%)	<0.001^a
Fibrinogen (mg/dl)	> 400 (mg/dl)	0 (0%)	28 (56%)	28 (28%)	<0.001^a
Fibrinogen (mg/dl)	< 400 (mg/dl)	50 (100%)	22 (44%)	72 (72%)	<0.001^a
Homocysteine (µmol/L)	> 15 (µmol/L)	13(26%)	26 (52%)	39 (39%)	0.008^a
Homocysteine (µmol/L)	< 15 (µmol/L)	37 (74%)	24 (48%)	61 (61%)	0.008^a
Anticardiolipin antibody (IgG) GPL units	> 10 GPL units	14 (28%)	50 (100%)	64 (64%)	<0.001^a
Anticardiolipin antibody (IgG) GPL units	< 10 GPL units	36 (72%)	0 (0%)	36 (36%)	<0.001^a
Anticardiolipin antibody (IgM) (MPL units)	>15 MPL units	2 (4%)	39 (78%)	41 (41%)	<0.001^a
Anticardiolipin antibody (IgM) (MPL units)	<15 MPL units	48 (96%)	11 (22%)	59 (59%)	<0.001^a

^aSignificant at the 0.05 probability level. ^bNS- Not significant at the 0.05 probability level. Group 1= ESRD patients with well functioning fistulas; Group 2= ESRD patients with failed AVF.